RECEIVED **CENTRAL FAX CENTER**

NOV 1 6 2005



Vertex Pharmaceuticals Incorporated 130 Waverly Street . Cambridge, MA 02139-4242 Tel. 617.444.6100 • Fax 617.444.6483 http://www.vrtx.com

FAX TRANSMISSION

| То | USPTO Commissioner for Patents |
|---|--------------------------------|
| Examiner | Kansay Habte |
| Fax Number | (571) 273-8300 |
| From | Karen E. Brown |
| Date | November 16, 2005 |
| Application No. | 10/700,936 |
| Attorney Docket No. | VPI/02-123US |
| , the same of the | Supplemental IDS |
| Total Pages | 40 |
| | |

Message or Comment

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence and any documents attached hereto, are being transmitted via facsimile to the United States Patent and Trademark Office, Facsimile Number (571) 273-8200 on November 16, 2005.

Lisa M. Romano

If any problems occur with this fax transmittal, please call (617) 444-6164 immediately.

FAX Number (617) 444-6483 Legal Department

RECEIVED CENTRAL FAX CENTER

NOV 1 6 2005

Docket No.: VPI/02-123 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| Application No.: Confirmation No.: | 10/700,936 5983 | | |
|------------------------------------|--------------------|--|--|
| Filing Date: | November 4, 2003 | | |

Filing Date: November 4, 200

Examiner: Kahsay Habte

Group Art Unit: 1624

Applicants: Randy S. Bethiel et al.

For: COMPOSITIONS USEFUL AS INHIBITOS OF JAK AND OTHER

PROTEIN KINASES

November 16, 2005 Cambridge, Massachusetts

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

| (a) | accom) | panying identific | 7 C.F.R. §1.56, it is requested that the documents listed on the Form 1449/PTO be considered and made of record in the ed patent application. |
|-----|-------------|------------------------------|---|
| | \boxtimes | Copy(i | es) of references Citation No(s). C1-C4 is attached |
| | | Copy(i applica applica | es) of references Citation No(s). was/were filed in this ation U.S. Application No(s). filed filed from which this ation claims priority under 35 U.S.C. § 120.). |
| | | | y of the International Search Report received in the corresponding application No is attached herewith. |
| (b) | | No fee | e is believed due because: |
| | | | The Information Disclosure Statement is being filed within three (3) months of the filing date of the application. |
| | | | The Information Disclosure Statement is being concurrently filed with the above-identified application. |
| | | | The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE). |

| Applican U.S.S.N.: | nts: | Bethie 10/700 | el et al. 0,936 | |
|-----------------------|------------|------------------|--------------------|---|
| (| (c) | \boxtimes | date of | The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits. formation Disclosure Statement is being filed before the mailing f any final action, notice of allowance or an action that otherwise prosecution; and |
| | | | | Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; |
| | | | | No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; |
| | | | \boxtimes | The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725. |
| | (d) | | The : | Information Disclosure Statement is being filed on or before the |
| | | | | Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; |
| | | | | No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and |
| | | | | The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725. |

APPLICANTS: U.S.S.N.:

Bethiel et al. 10/700,936

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. \boxtimes 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866

Attorney for Applicants

Vertex Pharmaceuticals Incorporated

130 Waverly Street Cambridge, Massachusetts 02139

Tel: (617) 444-6168 Fax: (617) 444-6483

RECEIVED CENTRAL FAX CENTER

NOV 1 6 2005

Docket No.: VPI/02-123 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| 10/700,936 | | |
|------------|--|--|
| 5983 | | |
| | | |

Confirmation No.:

3703

Filing Date:

November 4, 2003

Examiner:

Kahsay Habte

Group Art Unit:

1624

Applicants:

Randy S. Bethiel et al.

For:

COMPOSITIONS USEFUL AS INHIBITOS OF JAK AND OTHER

PROTEIN KINASES

November 16, 2005 Cambridge, Massachusetts

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

| | | | 4 4 4 |
|------------|-------------|-----------------------|--|
| (a) | 90000 | ipanying -identifi | 7 C.F.R. §1.56, it is requested that the documents listed on the Form 1449/PTO be considered and made of record in the ed patent application. |
| | \boxtimes | Copy(i | ies) of references Citation No(s). C1-C4 is attached |
| | | applic | ies) of references Citation No(s). was/were filed in ation U.S. Application No(s). filed, from which this ation claims priority under 35 U.S.C. § 120.). |
| | | | by of the International Search Report received in the corresponding Application No is attached herewith. |
| (b) | | No fe | e is believed due because: |
| () | _ | | The Information Disclosure Statement is being filed within three (3) months of the filing date of the application. |
| | | | The Information Disclosure Statement is being concurrently med |
| | | | The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE). |

| APPLICANTS: U.S.S.N.: | | el et al. 0,936 | |
|--------------------------|-------------|--------------------|---|
| | | | The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits. |
| (c) | \boxtimes | date of | formation Disclosure Statement is being filed before the maining fany final action, notice of allowance or an action that otherwise prosecution; and |
| | | | Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; |
| | | | No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or |
| | | \boxtimes | The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725. |
| . (d) | | The paym | Information Disclosure Statement is being filed on or before the |
| | | | Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; |
| | | | No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and |
| | | | The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725. |

APPLICANTS: U.S.S.N.:

Bethiel et al. 10/700,936

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. \boxtimes 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866

Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, Massachusetts 02139

Tel: (617) 444-6168 Fax: (617) 444-6483

RECEIVED CENTRAL FAX CENTER

BEST AVAILABLE COPY

NOV 1 6 2005

Page 1 of 1

| STAT | PRMATION DI PRMATI | Issue Date | | Application Number Filing Data First Named Invento Group Art Unit Examiner Name Attorney Docket Nu TENT DOCUMENTS tentoc(s) or Applicant(s) | r Ran 162 Kai mber VP | ember 4, 200 dy S. Bethiel 4 say Habte U02-123 US Sub Class | | ate opriate |
|--|--|--|---|---|--|--|---|---|
| STA: | U.S. Patent Document No. | Issue Date | Name of Pa | First Named Inventor Group Art Unit Examiner Name Attorney Docket Nu ENT DOCUMENTS tentoc(s) or Applicant(s) | Lieber VP. | 4 say Habte //02-123 US | | ate opriate |
| STA: | U.S. Patent Document No. | Issue Date | Name of Pa | Group Art Unit Examiner Name Attorney Docket Nu TENT DOCUMENTS tentce(s) or Applicant(s) | Lies Karmber VP | Isay Habte 1/02-123 US | Filing D. | ate apriate |
| itte Io. | U.S. Patent Document No. | Issue Date | Name of Pa | Examiner Name Attorney Docket Nu TENT DOCUMENTS tentcc(8) or Applicant(9) | Class | V02-123 US | Filing D. | ate opriate |
| ite O ₁ | U.S. Patent Document No. | Issue Date | Name of Pa | Attorney Docket Nu TENT DOCUMENTS tentce(a) or Applicant(s) | Class | Sub | Filing D. If Appro | ate opriate |
| ite O ₁ | U.S. Patent Document No. | Issue Date | Name of Pa | TENT DOCUMENTS tentce(s) or Applicant(s) | Class | S#b Class | Filing D | ate opriate |
| Cife | Document No. Foreign Patent D | | Name of Pa | tentcc(8) or Applicant(9) | | S#b Class | Filing D. | ate appriate |
| Cife | Document No. Foreign Patent D | | | | | Sub | Filing D. | ate opriate |
| Cife | Document No. Foreign Patent D | | | | | | | |
| | | ncement | FOREIGN | | | | | |
| | | ncervent | FOREIGN | | | | | |
| | | ncurrent | FOREIGN | | | | | |
| | | ocument. | FOREIGN | | | | | |
| | | ocument | FOREIGN | | | | | |
| | | ocument | FURLIUIT. | PATENT DOCUMENTS | | | | |
| | | DESTRICKE | | | Date | f Publication | Tron | siation No |
| | | | Name of Pa | Name of Patentee(s) or Applicant(s) | | | 100 | |
| | | | | | | | + - | |
| | | | | | | | ╀ - | |
| | | | <u> </u> | | | | <u> </u> | <u> </u> |
| | | | ION DATE | PART & FEEDATIDE BOX | UMENTS | | | |
| | | | | | | | | |
| Sxam Cite Inhibit No. Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. | | | | | | | cakemog | enėsis" |
| Cl | LS Steelman et al., "JAK/STAT, Rat/MEK/ERK, PI3K/Akt and BCR-ABL in Cell Cycle Progression And Deduction | | | | | | | |
| <u></u> | | | The Trigger", (| Опсовене 24: 7125-7126 (| 2005) | | | |
| C2 | Stefan Faderi et | al. "WP-1034, | A Novel JAK- | STAT Inhibitor, with Pros | poptotic and Antilei | kemic Activity | In Acme | MACIO |
| | Leukemia (AMI | .)". Anticancer l | Research 25: I | m of Specific Inhibitors C | f Janus Kinase 3 As | Apoptosis-Ind | ucing Anti | leuken |
| Ç4 | Agents", Clinica | a) Cancer Reseat | rch, 5; 1569-1 | 582 (1999) | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | <u> </u> | | | | | | | |
| | | | | | | | | |
| f this r | reference is not p | provided as it v | was previous | ly cited by or submitted | to the office in a | orior applicat | ion, S.C. §120 | <u> </u> |
| | | | | | . += | | | |
| OD, CC | munuanon-m-pe | | | | D | | | |
| ١. | | - | | | Date Considered | | | |
| N C C C C C C C C C C C C C C C C C C C | 00. 11 22 23 24 | LS Steelman et a Lcukemia 18: 16 Lcukemia 18: 16 Lcukemia 18: 16 Lcukemia (AMI Leukemia (AMI Leukemi | Name of Author, Title (when ap LS Steelman et al., "JAK/STAT Lcukemia 18: 189-218 (2004) Fruncois-Xavier Mahon, "JAK" Stefan Faderl et al., "WP-1034, Leukemia (AML)", Anticancer Elisa A. Sudbeck et al., "Struch Agents", Clinical Cancer Resea | Name of Author, Title (when appropriate), Page 1 LS Steelman et al., "JAK/STAT, Raf/MEK/Et Leukemia 18: 189-218 (2004) Francois-Xavier Mahon, "JAK The Trigger", Stefan Fadert et al., "WP-1034, A Novel JAK Leukemia (AML)". Anticancer Research 25: Hisa A. Sudbeck et al., "Structure-based Desi Agents", Clinical Cancer Research, 5; 1569-1 | Name of Author, Title (when appropriate), Publication, Volume, Page(9) LS Steelman et al., "JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-Al Loukemia 18: 189-218 (2004) Francois-Xavier Mahon, "JAK The Trigger", Oncogene 24: 7125-7126 (3) Stefan Faderi et al., "WP-1034, A Novel JAK-STAT Inhibitor, with Proal Leukemia (AML)". Anticancer Research 25: 1841-1850 (2005) Elisa A. Sudbeck et al., "Struchire-based Design of Specific Inhibitors Of Agents", Clinical Cancer Research, 5; 1569-1582 (1999) this reference is not provided as it was previously cited by or submitted this reference is not provided as it was previously cited by or submitted and reflict upon for an end relied upon end relied upon for an end relied upon end relied upon end relied upon end end end end end end en | Lukemia 18: 189-218 (2004) Stefan Faderi et al., "WP-1034, A Novel JAK-STAT Inhibitor, with Proapoptotic and Antileu Leukemia (AML)". Anticancer Research 25: 1841-1850 (2005) Elisa A. Sudbeck et al., "Structure-based Design of Specific Inhibitors Of Janus Kinase 3 As Agents", Clinical Cancer Research, 5: 1569-1582 (1999) this reference is not provided as it was previously cited by or submitted to the office in a justice and relied upon for an earlier filing date in, continuation-in-part, and divisional applications). Date Considered | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. LS Steelman et al., "JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in Cell Cycle Progression And Leukemia 18: 189-218 (2004) Francois-Xavier Mahon, "JAK The Trigger", Oncogene 24: 7125-7126 (2005) Stefan Faderi et al., "WP-1034, A Novel JAK-STAT Inhibitor, with Proapoptotic and Antileukemic Activity Leukemia (AML)", Anticancer Research 25: 1841-1850 (2005) Elisa A. Sudbeck et al., "Structure-based Design of Specific Inhibitors Of Janus Kinasa 3 As Apoptosis-Ind Agents", Clinical Cancer Research, 5: 1569-1582 (1999) this reference is not provided as it was previously cited by or submitted to the office in a prior application, filed, and relied upon for an earlier filing date under 35 U. Date Considered | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. LS Steelman et al., "JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in Cell Cycle Progression And Leukemogi Leukemia 18: 189-218 (2004) Francois-Xavier Mahon, "JAK The Trigger", Oncogene 24: 7125-7126 (2005) Stefan Faderl et al., "WP-1034, A Novel JAK-STAT Institute, with Proapoptotic and Antileukemic Activity in Acute Leukemia (AML)", Anticancer Research 25: 1841-1850 (2005) Elisa A Sudbeck et al., "Structure-based Design of Specific Inhibitors Of Janus Kinase 3 As Apoptosis-Inducing Anti-Agents", Clinical Cancer Research, 5; 1569-1582 (1999) this reference is not provided as it was previously cited by or submitted to the office in a prior application, filed, and relied upon for an earlier filing date under 35 U.S.C. §126 in, continuation-in-part, and divisional applications). |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Oraw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.